CRO Fortrea ‘disputes the accuracy’ of Acelyrin’s claims about immunology drug trial conduct

After Acelyrin said that a contract research organization and its vendor made “clinical trial execution errors” in a study of the biotech’s lead immunology treatment candidate, the CRO has responded and is pushing back against some of the claims.

North Carolina-based Fortrea, a large, decades-old CRO that recently Click here to view original post